Our findings instead suggest that low doses of rapamycin, by specifically inhibiting mTORC1, could be beneficial in pathological conditions where an excessive insulin secretion and signalling is present, such as in insulin resistance (Fig. 8). The gene discussed is INS; the disease is Insulin resistance.